免疫检查点抑制剂相关肌炎及三联重叠综合征
美国退伍军人回顾性队列研究(2011年6月至2022年2月)纳入29296例接受ICI治疗者,识别68例(0.2%)ICI诱导肌炎,其中23例为ICI三联综合征、45例为孤立性ICI肌炎。三联综合征中位生存2.5个月、6个月内死亡率60.0%,高于孤立性肌炎(20.4个月、30.2%)和无肌炎者(12.6个月、31.5%);6个月后三组死亡趋势相似。
要点
- ICI三联综合征(肌炎、心肌炎、重症肌无力)6个月内死亡率60.0%,中位生存仅2.5个月。
- 孤立性ICI肌炎死亡结局与未发生肌炎者相似,6个月后三组死亡趋势趋同。
- 接受ICI治疗的退伍军人中ICI诱导肌炎发生率为0.2%(68/29296)。
核心结论
- ICI三联综合征在首次ICI治疗后前6个月内与更高的总死亡率和更短的中位生存时间相关。
- 孤立性ICI肌炎与未发生肌炎的ICI治疗患者相比死亡结局相似。
研究设计与样本
- 美国退伍军人全国回顾性队列研究,纳入2011年6月至2022年2月接受ICI治疗者29296例。
- 通过ICI治疗后肌酸激酶(CK)升高和/或病历记录「肌炎」识别候选病例,经病历复核确认ICI相关肌炎并分为孤立性ICI肌炎或ICI三联综合征。
主要发现
- 29296例接受ICI治疗的退伍军人中识别68例(0.2%)ICI诱导肌炎,包括23例ICI三联综合征和45例孤立性ICI肌炎。
- ICI三联综合征中位生存2.5个月(95%CI 1.7-18.5),孤立性ICI肌炎为20.4个月(95%CI 6.2-60),无肌炎ICI治疗者为12.6个月(95%CI 12.3-12.8)。
- ICI治疗开始后6个月内死亡率:三联综合征60.0%,孤立性ICI肌炎30.2%,无肌炎者31.5%。
- 首次ICI治疗后6个月,三组后续死亡趋势相似。
临床怎么用
- 对ICI治疗患者应警惕肌炎,尤其合并心肌炎和重症肌无力的三联综合征,其前6个月死亡风险高。
- 孤立性ICI肌炎的远期死亡风险与未发生肌炎者相似,提示需重点管理三联综合征而非所有肌炎。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all-cause mortality in these patients. METHODS: We performed a national retrospective cohort study of US veterans treated with an ICI between June 2011 and February 2022. Cases were identified by elevated creatinine kinase (CK) following ICI therapy and/or "myositis" in notes. Chart review determined if candidates had ICI-associated myositis and were subsequently classified as isolated ICI myositis or ICI triad syndrome. RESULTS: Of 29,296 veterans treated with ICIs, 68 (0.2%) ICI-induced myositis cases were identified, including 23 patients with ICI triad syndrome and 45 patients with isolated ICI myositis. Median survival duration for ICI triad syndrome was 2.5 (95% confidence interval [CI] 1.7-18.5) months in comparison to 20.4 (95% CI 6.2-60) months for isolated ICI myositis and 12.6 (95% CI 12.3-12.8) months median survival for patients treated with ICI without myositis. Patients with ICI triad syndrome had 60.0% mortality during the six months following initiation of ICI treatment, in comparison to 30.2% mortality in isolated ICI myositis and 31.5% mortality in patients without myositis. Six months after the first ICI treatment, subsequent mortality trends were similar in the three groups. CONCLUSION: ICI triad syndrome is associated with higher overall mortality and shortened median survival times during the first six months after initial ICI therapy, whereas isolated ICI myositis is associated with similar mortality outcomes compared to patients treated with ICI who did not develop myositis.
引用
- Rubino S, Cannon GW, Sauer BC, et al. Immune Checkpoint Inhibitor-Related Myositis and Associated Triad Overlap Syndrome. Arthritis Care Res (Hoboken). 2026. PMID: 41664543. doi:10.1002/acr.80015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。